In this second edition of Primer on Multiple Sclerosis, the latest updates on therapeutics will be provided, including new medications that have been FDA- approved since the first edition. New diagnostic criteria is included, as well as any advances made in current diagnostic techniques, e.g. new imaging metrics. Important new information in the basic sciences and pathophysiology of MS are provided as well as newer epidemiologic studies. Treatment algorithms for common symptoms will be expanded, as well as any new guidelines for switching medications for Disease Modifying treatment "failures". The chapter on alternative and complimentary therapies will discuss new research on CCSVI. The chapter on legal issues will include information on the putative effect of the Affordable Health Care Act on access to neurologic care and treatments. Finally, there is expanded discussion of progressive forms of MS both from a basic science and treatment perspective.
{{comment.content}}